Clearmind Medicine Secures $1.575M in Highly Dilutive Convertible Note Financing
CMND sits 54% above its 52-week low of $0.595 on elevated volume (37× avg).
Summary
Clearmind Medicine Inc. has issued convertible promissory notes for $1.575 million in cash, representing a substantial capital raise relative to its market capitalization but implying significant future dilution.
Key Events · Financing and Capital Events · CMND
-
Secures $1.575 Million in Cash
Clearmind Medicine Inc. received $1,575,000 in cash from the issuance of convertible promissory notes.
-
Highly Dilutive Financing
The notes have an aggregate principal amount of $1,750,000 and were issued at a 10% discount, implying significant future dilution upon conversion.
-
Execution of Prior Agreement
This financing is an execution of securities purchase agreements originally entered into on September 17, 2025, for up to $10,000,000 in convertible notes.
Analysis · CMND · Life Sciences
This filing announces the execution of a previously established securities purchase agreement, resulting in Clearmind Medicine Inc. receiving $1.575 million in cash from the issuance of convertible promissory notes. While this capital infusion is critical for a micro-cap company with a market capitalization of approximately $1.9 million, the financing terms involve a 10% discount to the principal amount of $1.75 million and the notes are convertible, indicating substantial potential dilution for existing shareholders. This move provides essential operating capital but at a high cost to equity holders.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 42.7% of the 487 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.59 to $52.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.